



## Gold and Silver Complexes in the Treatment of Diseases 2.0

Guest Editor:

**Prof. Dr. María Jesús  
Rodríguez-Yoldi**

Department of Physiology and  
Pharmacology, Physiology Unit,  
Veterinary Faculty, University of  
Zaragoza, 50009 Zaragoza, Spain

Deadline for manuscript  
submissions:

**closed (31 May 2024)**

### Message from the Guest Editor

At present, metal pharmaceuticals offer a new perspective in pharmacology and medicine. The growing development of so-called bioinorganic chemistry based on new drugs derived from metal complexes opens new possibilities in the treatment of diseases. In recent decades, gold complexes have been tested against HIV for the treatment of AIDS, acute forms of chronic asthma, and pemphigus (an autoimmune skin disease) and in the treatment of malaria, Chagas disease, and cancer. On the other hand, silver complexes have been used in the treatment of childhood blindness (ophthalmia neonatorum) and as antimicrobial agents for many years, and their antitumor potential is currently being studied. In recent years, the use of metal complexes as chemotherapeutic agents is gaining importance. Likewise, the use of nanoparticles as chemotherapeutic agents to transport metal complexes is beginning to be investigated.

This Special Issue may publish original research papers and reviews on aspects related to gold and silver complexes in the treatment of diseases, highlighting the mechanism of action and targets involved in its therapeutic properties.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)